The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Official Title: A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Study ID: NCT06161025
Brief Summary: This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer
Detailed Description: This study will focus on R-DXd in participants with platinum-resistant, high-grade ovarian, primary peritoneal, or fallopian tube cancer. R-DXd is an antibody-drug conjugate that specifically binds to CDH6, which is overexpressed in tumor cells. The Phase 2 dose-optimization part of the study (Part A) intends to define the recommended dose based on safety and efficacy, while the Phase 3 (Part B) part of the study will compare R-DXd with Investigator's choice of chemotherapy and further evaluate efficacy.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Fudan University Shanghai Cancer Center, Shanghai, , China
National Cancer Center Hospital, Chuo-ku, , Japan
NHO Kyushu Cancer Center, Fukuoka-shi, , Japan
Saitama Medical University International Medical Center, Hidaka-shi, , Japan
National Cancer Center Hospital East, Kashiwa-shi, , Japan
Cancer Institute Hospital of JFCR, Koto-ku, , Japan
Jikei University Hospital, Minato-ku, , Japan
Aichi Cancer Center Hospital, Nagoya-shi, , Japan
Niigata Cancer Center Hospital, Niigata-shi, , Japan
Osaka International Cancer Institute, Osaka-shi, , Japan
Hokkaido University Hospital, Sapporo-shi, , Japan
Iwate Medical University Hospital, Shiwa-gun, , Japan
Taipei Veterans General Hospital, Taipei, , Taiwan
Name: Global Clinical Leader
Affiliation: Daiichi Sankyo
Role: STUDY_DIRECTOR